欢迎光临源叶生物,登录 | 注册 |
当前位置: 首页 > 小分子抑制剂 > Autophagy > Cilofexor

浏览历史

S88391

Cilofexor

源叶(MedMol) 98%
  • 英文名:
  • Cilofexor
  • 别名:
  • CAS号:
  • 1418274-28-8
  • 分子式:
  • C28H22Cl3N3O5
  • 分子量:
  • 586.85
  • 核磁/质谱:
品牌货号产品规格价格(RMB) 库存(上海) 北京 武汉 南京 数量计量单位 加入购物车...
源叶(MedMol) S88391-2mg 98% ¥765.00元 5 - - - EA 加入购物车
源叶(MedMol) S88391-5mg 98% ¥1220.00元 6 - - - EA 加入购物车
源叶(MedMol) S88391-10mg 98% ¥1970.00元 6 - - - EA 加入购物车
源叶(MedMol) S88391-25mg 98% ¥3900.00元 6 - - - EA 加入购物车
源叶(MedMol) S88391-50mg 98% ¥5600.00元 预计交期:2-3天 - - - EA 加入购物车
大包装询价

提交您的电话号码并同意《个人信息授权与保护申明》,到货后将短信提示。
提交

产品介绍

参考文献

质检证书(COA)

摩尔浓度计算器

相关产品

  • 产品描述: Cilofexor (GS-9674) is a potent, selective and orally active nonsteroidal FXR agonist with an EC50 of 43 nM. Cilofexor has anti-inflammatory and antifibrotic effects. Cilofexor has the potential for primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH) research
  • 靶点: EC50: 43 nM (FXR);FXR; Autophagy
  • 体内研究:
    Cilofexor (GS-9674; 30 mg/kg; oral gavage; once daily; for 10 weeks; male Wistar rats) treatment significantly increases Fgf15 expression in the ileum and decreased Cyp7a1 in the liver in nonalcoholic steatohepatitis (NASH) rats. Liver fibrosis and hepatic collagen expression are significantly reduced. Cilofexor also significantly reduces hepatic stellate cell (HSC) activation and significantly decreases portal pressure, without affecting systemic hemodynamics. Animal Model: Male Wistar rats received a choline-deficient high fat diet (CDHFD) Dosage: 30 mg/kg Administration: Oral gavage; once daily; for 10 weeks Result: Significantly increased Fgf15 expression in the ileum and decreased Cyp7a1 in the liver. Liver fibrosis and hepatic collagen expression were significantly reduced.
  • 参考文献:
    1. Trauner M, et al. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. Hepatology. 2019 Sep;70(3):788-801. 2. Patel K, et al. Cilofexor, a Nonsteroidal FXR Agonist, in Non-Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial. Hepatology. 2020 Mar 1. 3. P. Schwab, et al. The FXR agonist GS-9674 reduces fibrosis and portal hypertension in a rat model of NASH. April 2018,Volume 68, Supplement 1, Pages S471-S472.
  • 溶解性: Soluble  in  DMSO
  • 保存条件: -20℃
  • 配置溶液浓度参考:
    1mg 5mg 10mg
    1 mM 1.704 ml 8.52 ml 17.04 ml
    5 mM 0.341 ml 1.704 ml 3.408 ml
    10 mM 0.17 ml 0.852 ml 1.704 ml
    50 mM 0.034 ml 0.17 ml 0.341 ml
  • 注意:部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。
输入产品批号:

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:


质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)


  • =
    *
    *


源叶所有产品仅用作科学研究,销售产品行为均适用于我司网上所列通用销售条款。